<DOC>
	<DOC>NCT00730262</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.</brief_summary>
	<brief_title>Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirmed Glioblastoma Multiforme (GBM) Prior treatment with radiation and one first line systemic therapy (including temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination therapies), followed by measurable and unequivocal evidence of tumor progression or recurrence Age ≥ 18 years ECOG ≤ 2 Normal organ and marrow function as defined below: leukocytes ≥3 x 109/L absolute neutrophil count ≥1.5 x 109/L platelets ≥100 x 109/L hemoglobin ≥90 g/L total bilirubin ≤2.5 X institutional upper limit of normal AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal creatinine ≤1.0 X institutional upper limit of normal Patients with a life expectancy &lt; 12 weeks Patients with a documented history of HIV, active hepatitis B or C infections Female patients who are pregnant or lactating Patients in whom a proper central line (Portacathlike device) cannot be established Patients with a known hypersensitivity to farnesylated dibenzodiazepinone or polysorbate 80 Patients with uncontrolled hypotension Patients with concomitant therapy of therapeutic coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Glioblastoma Multiforme (GBM)</keyword>
	<keyword>Phase II</keyword>
	<keyword>Brain Cancer</keyword>
</DOC>